Life Sciences Tools and Services
Company Overview of Theranostics Health, LLC
Theranostics Health, LLC (TH) designs and develops healthcare and disease management systems. The company offers a technology platform, including fixative reagents that are developed to preserve cell morphology and fix the state of cellular activities for molecular analysis; laser capture microdissection, which is used to isolate specific cell populations from various types of cells present in a clinical biopsy; and reverse phase protein microarray that enables sensitive, quantitative, calibrated, and multiplexed analysis of cellular proteins from a limited amount of starting materials, such as clinical specimens. It also develops clinical tests, including THX-100, which provides information...
15010 Broschart Road
Rockville, MD 20850-6365
Founded in 2006
Key Executives for Theranostics Health, LLC
Vice President of Business Development
Executive Director of Clinical Research
Senior Director of Sales and Marketing
Compensation as of Fiscal Year 2013.
Theranostics Health, LLC Key Developments
med fusion and Theranostics Health, LLC to Introduce First of the TheraLink Assays for Use in Patients with Malignant Diseases; To Announce Distribution Agreement for TheraLink(TM) HER Family Assay
May 29 13
med fusion and Theranostics Health, LLC will introduce the first of the TheraLink(TM) Assays for use in patients with malignant diseases at the American Society of Clinical Oncology (ASCO) Annual '13 Meeting, held in Chicago, IL from May 31, 2013 through June 4, 2013. The TheraLink(TM) HER Family Assay for primary, recurrent and metastatic breast cancers provides a molecular analysis of each patient's unique cancer, based upon the functional activity of signal transduction pathways known to modulate cancerous growth. This 'theranostic' assay provides a comprehensive molecular profile of the HER family of cell surface receptors and three key signaling pathways modulated by the HER family which have important roles in the therapeutic approach to treating breast cancer. The TheraLink(TM) HER Family Assay is the first in a series of similar assays based upon measuring a panel of analytes, including a number of drug targets.
med fusion and Theranostics Health will also announce that they are entering into an exclusive distribution agreement for Theranostics Health's TheraLink(TM) HER Family Assay. Under the terms of the agreement, med fusion and its affiliate, Pathologists Bio-Medical Laboratories (PBM), will provide a gateway for access to the theranostic test for the McKesson Network of oncologists, which includes US Oncology and Texas Oncology and to the oncologists of the Baylor Healthcare System. Oncologists will be able to order the assay through their pathology services directly from med fusion.
Theranostics Health, LLC Presents at Mid-Atlantic Bio Conference, Sep-27-2012
Aug 17 12
Theranostics Health, LLC Presents at Mid-Atlantic Bio Conference, Sep-27-2012 . Venue: Bethesda North Marriott Hotel & Conference, Bethesda, Maryland, United States.
Med Fusion, LLC Partners with Theranostics Health, LLC to Advance Personalized Medicine for Patients with Cancer
Aug 15 12
Med Fusion, LLC and Theranostics Health, LLC have entered into a Market Development Agreement to validate the clinical utility of Theranostics' TheraLink(TM) Assays for use in patients with malignant diseases. The goal of this relationship is to help accelerate advancement of new methods in molecular diagnostics testing and their use in personalized predictive treatments. Med Fusion announced it has entered into a Market Development Agreement with Theranostics Health Inc. to clinically validate diagnostic assays based on measuring the activation status of signal transduction pathways important to the development and growth of human cancers. Theranostic's TheraLink(TM) Assays are designed to provide oncologists with a molecular map based on each individual cancer's unique pattern of aberrant signaling. This approach will allow oncologist to exploit each tumor's individual molecular profile and therefore provide truly personalized treatment to each patient. In addition, the companies will jointly conduct promotional, marketing and sales-related efforts, technology integration, as well as other activities aimed at the clinical services, clinical trials, diagnostic, theranostic and personalized healthcare markets. Under the terms of the agreement, the companies will work together to provide clinical validation of the TheraLink(TM) Assays through clinical trials conducted by med fusion as well as through other oncology practices associated with med fusion. The TheraLink(TM) Assays will provide oncologists access to information about the activity of signaling pathways that are out of control in cancer and the activity of drug targets in these pathways as they seek to provide better care for their patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 12, 2013
July 9, 2013